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Background: Vertebral artery origin (VAO) stenosis is occasionally observed in patients who have acute ischemic
stroke. We investigated the long-term outcomes and clinical significance of VAO stenosis in patients with acute
ischemic stroke.
Methods: We performed a prospective observational study using a single stroke center registry to investigate the
risk of recurrent stroke and vascular outcomes in patients with acute ischemic stroke and VAO stenosis. To relate
the clinical significance of VAO stenosis to the vascular territory of the index stroke, patients were classified into an
asymptomatic VAO stenosis group and a symptomatic VAO stenosis group.
Results: Of the 774 patients who had acute ischemic stroke, 149 (19.3%) of them had more than 50% stenosis of the
VAO. During 309 patient-years of follow-up (mean, 2.3 years), there were 7 ischemic strokes, 6 hemorrhagic strokes, and
2 unknown strokes. The annual event rates were 0.97% for posterior circulation ischemic stroke, 4.86% for all stroke, and
6.80% for the composite cardiovascular outcome. The annual event rate for ischemic stroke in the posterior circulation
was significantly higher in patients who had symptomatic VAO stenosis than in patients who had asymptomatic
stenosis (1.88% vs. 0%, p = 0.046). In a multivariate analysis, the hazard ratio, per one point increase of the Essen Stroke
Risk Score (ESRS) for the composite cardiovascular outcome, was 1.46 (95% CI, 1.02-2.08, p = 0.036).
Conclusions: Long-term outcomes of more than 50% stenosis of the VAO in patients with acute ischemic stroke were
generally favorable. Additionally, ESRS was a predictor for the composite cardiovascular outcome. Asymptomatic VAO
stenosis may not be a specific risk factor for recurrent ischemic stroke in the posterior circulation. However, VAO
stenosis may require more clinical attention as a potential source of recurrent stroke when VAO stenosis is observed in
patients who have concurrent ischemic stroke in the posterior circulation.Background
A recent systematic review revealed that the recurrence
rates of stroke and vascular events in medical secondary
stroke prevention trials have declined substantially over
the last 5 decades [1]. For recurrent stroke, the annual
rate fell from 8.7% in trials that began in the 1960s to
4.9% in trials that began in the 2000s [1].
Atherosclerosis of the vertebrobasilar artery is one of
the major causes of ischemic stroke in the posterior circu-
lation [2,3]. The most proximal portion of the extracranial
vertebral artery is the second most common area of* Correspondence: hykimmd@gmail.com
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reproduction in any medium, provided the orstenosis, next to the carotid bifurcation [4]. In clinical
practice, stenosis of vertebral artery origin (VAO) is occa-
sionally observed in patients who have acute ischemic
stroke. In a hospital-based cohort that consisted of pa-
tients who had various atherosclerotic arterial diseases,
the risk of ischemic stroke in the posterior circulation was
higher in patients who had VAO stenosis than in those
who did not have VAO stenosis (annual rate, 0.4% vs.
0.1%), even though the annual rate was very low [5]. How-
ever, VAO stenosis has not been well studied as a risk fac-
tor for stroke recurrence in patients with acute ischemic
stroke, especially for posterior circulation ischemic stroke.
Previous case series studies have reported controversial re-
sults. Stenosis of VAO could be an important embolic
source for ischemic stroke in the posterior circulation
[3,6-9] or could be a benign condition because there is a. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tery or branches of the external carotid artery [10,11]. A
recent pooled analysis study indicated that symptomatic
vertebrobasilar stenosis can be a strong predictor of stroke
recurrence [12]. Our study was performed to investigate
the long-term outcomes in patients who had acute ische-
mic stroke and VAO stenosis and to examine the clinical
significance of VAO stenosis as a potential risk factor for
ischemic stroke in the posterior circulation or other car-
diovascular outcomes.
Methods
Patient inclusion and clinical assessments
The subjects used in this study were a subset of patients
enrolled in the Konkuk Stroke Registry, a single-center
prospective observational cohort study that has been de-
scribed elsewhere [13,14]. We evaluated the risk of re-
current stroke and vascular outcomes in patients with
acute ischemic stroke and VAO stenosis who were re-
cruited consecutively from December 2007 to December
2010. Acute ischemic stroke was confirmed by diffusion-
weighted MRI (DWI), which was performed within
5 days from the onset of stroke in patients who had been
admitted consecutively to our center within 72 h after
their stroke-onset. Based on the contrast-enhanced MR
angiography (CE-MRA) data, trained neurologists (YJ
Kim or JH Lee) determined the degree of VAO stenosis
through a modified method according to the North
American Symptomatic Carotid Endarterectomy Trial
[15]. Patients who had more than 50% stenosis of the
VAO on CE-MRA images were recruited for the study.
In cases of discrepancy, a senior stroke neurologist (HY
Kim) made the final decision. Patients who underwent
angioplasty and stenting for VAO stenosis in the acute
period of the index stroke were excluded from the study.
These exclusions were made because the purpose of our
study was to investigate the long-term outcomes under
optimal medical treatment.
Vascular risk factors, which included hypertension, dia-
betes mellitus, hyperlipidemia, cardiac arrhythmia, smok-
ing, peripheral arterial disease, and previous stroke
history, were evaluated. To determine the role of multiple
simultaneous risk factors, we evaluated risk profiles using
the Essen Stroke Risk Score (ESRS). The ESRS was useful
as a predictor of stroke recurrence; we calculated a sum
score (0–9 points) based on the following risk factors: 2
points for age >75 years and 1 point each for ages 65–
75 years, hypertension, diabetes mellitus, previous myo-
cardial infarction, other cardiovascular diseases, peripheral
arterial disease, current or past (<5 years) smoking, and
previous transient ischemic attack (TIA) or ischemic
stroke history in addition to the qualifying event [16].
Acute stroke care and optimal medical treatment for
secondary stroke prevention were performed based onstroke guidelines [17]. Acute stroke care was performed
in the stroke unit, and optimal medical treatment for
secondary prevention included modification of blood
pressure, lipid profile and glucose intolerance, treatment
using antithrombotics and statins, and encouraging pa-
tients for better compliance. The primary outcome vari-
able was recurrent stroke of any type. Secondary
outcomes included composite cardiovascular events
(nonfatal stroke, hospitalization for unstable angina,
nonfatal myocardial infarction, and vascular death) and
non-vascular death. Recurrent stroke was defined as an
acute neurological event that has focal symptoms and
signs consistent with a brain lesion and lasting for more
than 24 h. Whenever available, a brain CT or MRI was
obtained at the time of the recurrent neurological events
to confirm the type of recurrent stroke. Posterior circu-
lation ischemic stroke was defined as clinical symptoms
correlated with new lesions in the brainstem, cerebel-
lum, or occipital lobe in the vascular territory of verteb-
robasilar circulation. Anterior circulation ischemic
stroke was defined as clinical symptoms correlated with
new lesions in the vascular territory of the anterior cere-
bral artery, middle cerebral artery, or internal carotid ar-
tery. Hemorrhagic stroke was defined as either a
parenchymal, subarachnoid, or intraventricular hemorr-
hage detected on a brain CT or MRI that is associated
with the recurrent neurological events. In cases where
brain imaging could not be obtained by investigators, if
recurrent stroke was confirmed by telephone interview,
it was classified as unknown stroke. Deaths directly re-
lated to the stroke, myocardial infarction, or other vas-
cular causes within 28 days of the patient first being
seen were classified as vascular death. Patient follow-ups
were conducted either by a face-to-face interview at an
outpatient clinic with a physician or by a telephone
interview with a trained nurse at 3 months, 1 year, and
every year thereafter. Based on the mean follow-up
period used in previous studies of patients who had
angioplasty and stenting of the vertebral artery [18], the
duration of follow-up was designed to be at least 2 years.
This study was approved by the Konkuk University
Medical Center Institutional Review Board as a pro-
spective observational study.
MR imaging study
All MR examinations were performed using a 3 T MR
scanner (Signa HDx; GE Healthcare, Milwaukee, WI,
USA) with an 8-channel head coil. T1-, T2-weighted,
fluid attenuation inversion recovery, T2* gradient-echo,
DWI, and intra- and extracranial MRA were obtained.
T1-weighted, T2-weighted, and DWI were obtained
during the same imaging session and in the same orien-
tation and slice position: matrix = 512 × 224 in T1-
weighted, 384 × 384 in T2-weighted and 128 × 128 in
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weighted and 240 × 240 mm in DWI; section thickness
= 5 mm in T1 and T2-weighted and 3.5 mm in DWI;
intersection space = 2 mm in T1 and T2-weighted and
0 mm in DWI; and diffusion gradient strength, two b
values = 0 and 1000 s/mm2. The MRA consisted of
three-dimensional time-of-flight (TOF) sequences with
the following parameters: repetition time (TR) = 24 ms;
echo time (TE) = 2.6 ms; acquisition = 1; flip angle = 20°;
matrix of 512 × 512 using zero-fill interpolation = 384 ×
224; effective section thickness = 0.6 mm; and field of
view = 220 × 220 mm. Additionally, CE-MRA was per-
formed for the evaluation of neck vessels using the time-
resolved method. A typical injection protocol consisted
of a bolus injection of 10 mL of gadobutrol (Gadovist®
1.0; Bayer Schering Pharma AG, Berlin, Germany) at a
rate of 2.0 mL/s, followed by flushing with 35 mL of sa-
line bolus at the same rate. CE-MRA was acquired with
a three-dimensional gradient echo sequence using the
time-resolved method (Time-Resolved Imaging of Con-
trast Kinetics, TRICKS). The acquisition parameters for
CE-MRA were as follows: TR/TE = 3/1.1 ms; flip angle
= 20°; matrix = 320 × 192; slice thickness = 2.8 mm; field
of view = 320 × 160 mm; and a bandwidth = 83.33 kHz.
Three-dimensional volume acquisitions were coronally
oriented with section coverage from the aortic arch to
the circle of Willis and laterally to both subclavian arter-
ies. Moreover, volume acquisitions were conducted in 13
temporal phases with a temporal resolution time of 2.4 s
and a total scan time of approximately 41 s. Each three-
dimensional image set was viewed as a coronal
maximum-intensity projection.A Diffusion-weighted MRI Contrast enhanced MRA Vertebral artery or
B
Figure 1 Classification of vertebral artery origin stenosis. Representativ
acute infarcts were observed in the anterior circulation and symptomatic s
only in the posterior circulation. Arrowheads indicate stenosis of vertebral aOther clinical considerations
To relate the clinical significance of VAO stenosis to the
vascular territory of the index stroke, patients were clas-
sified into an asymptomatic VAO stenosis group when
acute infarcts were observed in the anterior circulation
(Figure 1A) or into a symptomatic VAO stenosis group
when acute infarcts were observed only in the posterior
circulation (Figure 1B). Because symptoms of posterior
circulation TIA can be vague, TIA patients who did not
have acute ischemic lesions on DWI were excluded from
our study. Infarcts in the vascular territory of the poster-
ior inferior cerebellar artery (PICA) and VAO stenosis
on the side contralateral to the infarct were also in-
cluded in the symptomatic VAO stenosis group because
PICA branching from basilar artery, anterior inferior
cerebellar artery, or contralateral vertebral artery is not a
rare variation [19]. However, we could not confirm these
variations because we did not perform conventional
angiography routinely. The presence of concurrent se-
vere cerebrovascular atherosclerosis, including concur-
rent severe steno-occlusion of the contralateral vertebral
artery, tandem stenosis of the intracranial vertebrobasilar
artery or severe concurrent carotid stenosis, and stroke
subtype were evaluated as possible risk factors for long-
term outcome. Stroke subtypes were classified by two
neurologists (JH Lee and HY Kim) according to the
modification of the Trial of Org 10172 in Acute Stroke
Treatment classification [20]. Because the aim of our
study was to investigate the clinical significance of VAO
stenosis, VAO stenosis was not considered as the sten-
osis responsible for the stroke subtype of large artery
atherosclerosis. Stroke subtype in some patients whoigin stenosis
CE-MRA performed
(n=819)




Stroke of other determined etiology (n=25)
Poor imaging quality (n=20)
No MR study (n=25)
- Poor cooperation due to unstable medical or 
neurological status (n=16)
- Pacemaker (n=4)
- Low economic status (n=5)
Incomplete MR study
- TOF MRA only (n=21)
More than 50% VAO 
stenosis (n=149)
No or less than 50% VAO stenosis (n=625) 
Enrolled patients 
(n=137)
Angioplasty and stenting for VAO stenosis (n=12) 
C
e cases of asymptomatic stenosis of vertebral artery origin (A) when
tenosis of vertebral artery origin (B) when acute infarcts were observed
rtery origin. (C) Patient inclusion flowchart.
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tery occlusion or cardioembolism instead of two or more
causes if they had no other concurrent significant stenosis
in the vertebrobasilar system except for VAO stenosis.
Statistical analysis
The chi square test or Fisher’s exact test was used to com-
pare categorical variables, and the t test was used to com-
pare continuous variables, when appropriate. Data were
censored at the time of outcome or at the last follow-up
assessment. Annual event rates for the study outcomes
were calculated as the number of outcomes divided by the
patient-years of follow-up. Cardiovascular outcome-free
survival was analyzed using Kaplan-Meier survival curves.
Univariate and multivariate Cox proportional hazard ana-
lyses were used to identify risk factors for recurrent stroke
or composite cardiovascular events. A p value of < 0.05
was considered statistically significant. Statistical analyses
were performed using SPSS version 17.0.
Results
Patient inclusion
Of the 865 consecutive patients who had acute ischemic
stroke, 25 patients (2.9%) did not undergo an MRI studyTable 1 Baseline characteristics of patients with asymptomat
Total (n = 137)
Asy
Age, years (mean ± SD) 70.4 ± 10.3
Male (n,%) 73 (53.3)
Hypertension (n,%) 96 (70.1)
Diabetes (n,%) 66 (48.2)
Hyperlipidemia (n,%) 56 (40.9)
Atrial fibrillation (n,%) 6. (4.4)
Smoking (n,%) 61 (44.5)
Previous stroke history (n,%) 34 (24.8)
Coronary arterial disease 27 (19.7)
Peripheral arterial disease 5 (3.6)
ESRS (mean ± SD) 3.2 ± 1.5
Concurrent vertebrobasilar stenosis* 42 (30.7)
Concurrent carotid stenosis† 28 (20.4)
Stroke subtype
Small artery occlusion 39 (28.5)
Large artery atherosclerosis 48 (35.0)
Cardioembolism 11 (8.0)
Two or more causes 16 (11.7)
Negative evaluation 23 (16.8)
*indicates the presence of concurrent severe stenosis or occlusion of the contralate
basilar artery.
†indicates the concurrent presence of more than 50% stenosis of at least one carot
ESRS Essen Stroke Risk Score.because of the various following reasons: severe neuro-
logical deficits (due to unstable medical or neurological
status arising from consciousness disturbance, severe de-
mentia, or mechanical ventilator management, n = 16),
use of a pacemaker (n = 4), and low economic status
(n = 5) (Figure 1C). Patients who underwent TOF-MRA
only, which could not cover the proximal neck vessels,
were excluded (n = 21). To maintain homogeneity in pa-
tient selection, patients who had strokes of other deter-
mined etiology were excluded (n = 25). In addition, 20
patients who provided poor image quality of their prox-
imal neck vessels were excluded from the final analysis.
Among the 774 patients who were eligible for the CE-
MRA analysis of VAO, 149 (19.3%) had more than 50%
stenosis of VAO. Additionally, 12 patients who under-
went angioplasty and stenting for VAO stenosis within
1 month after stroke-onset were excluded. The mean
age was 70.4 ± 10.3 years, and other baseline characteris-
tics are listed in Table 1. When comparing the asymp-
tomatic and symptomatic VAO stenosis groups,
concurrent vertebrobasilar stenosis was more prevalent
in patients with symptomatic VAO stenosis (21.9% in
the asymptomatic group vs. 38.4% in the symptomatic
group, p = 0.037) (Table 1).ic or symptomatic vertebral artery origin stenosis
Vertebral artery origin stenosis
P-value
mptomatic (n = 64) Symptomatic (n = 73)
71.5 ± 10.8 69.5 ± 9.9 0.247
40 (62.5) 33 (45.2) 0.043
46 (71.9) 50 (68.5) 0.666
30 (46.9) 36 (49.3) 0.776
28 (43.8) 28 (38.4) 0.522
4 (6.3) 2 (2.7) 0.316
29 (45.3) 32 (43.8) 0.862
20 (31.3) 14 (19.2) 0.103
12 (18.8) 15 (20.5) 0.792
2 (3.1) 3 (4.1) 0.759
3.3 ± 1.5 3.1 ± 1.4 0.339
14 (21.9) 28 (38.4) 0.037
16 (25.0) 12 (16.4) 0.215
0.304
21 (32.8) 18 (24.7)
24 (37.5) 24 (32.9)
6 (9.4) 5 (6.8)
4 (6.3) 12 (16.4)
9 (14.1) 14 (19.2)
ral vertebral artery, or tandem stenosis of intracranial vertebral artery or
id artery.
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Among 49 VAO stenoses (more than 50% in CE-MRA)
in the 37 patients who underwent both CE-MRA and
conventional angiography, 8 (16.3%) exhibited less than
50% stenosis in conventional angiography. More than
50% stenosis was concordant in the remaining 41 VAO
stenoses (83.7%). However, the degree of stenosis mea-
sured by CE-MRA was somewhat overestimated com-
pared to the degree measured using conventional
angiography.
Performance of the optimal medical treatment
As indicators of risk factor control, blood pressure, lipid
profile, and HbA1c level were measured. Profiles of
these indicators were improved at 3 and 12 months of
follow-up. Intensity of the optimal medical treatment
was also assessed by compliance to taking medication,
which included antihypertensive drugs, antithrombotics,
or statins. Almost all patients were on antithrombotics
(> 90%), and most patients were taking antihypertensive
drugs and statins (> 70%) at 3 and 12 months of follow-
up. Compared to the baseline, follow-up profiles of
blood pressure, total cholesterol, LDL cholesterol, andTable 2 Risk factor control and medication assessed at 3 and






Number of evaluated patients
Antihypertensive drug (n,%)
Antiplatelet agent or oral
anticoagulant (n,%)
Statin (n,%)






Number of evaluated patients
Antihypertensive drug (n,%)
Antiplatelet agent or oral
anticoagulant (n,%)
Statin (n,%)
Values denote mean ± SD or numbers with percentages in parentheses. n number o
Significantly improved compared to profiles of the baseline: *p < 0.001, †p < 0.01, ‡p
§HbA1c was measured in patients with diabetes mellitus.
VAO vertebral artery origin.HbA1c were significantly improved in both groups
(Table 2). The performance of optimal medical treat-
ment for risk factor management and control was ad-
equate in both groups.
Stroke recurrence and vascular outcome
The mean follow-up period was 2.3 ± 1.2 years for a total
of 309 patient-years. During the follow-up period, there
were 7 ischemic strokes (3 in the posterior circulation
and 4 in the anterior circulation), 6 hemorrhagic strokes,
2 unknown strokes, and 21 composite cardiovascular
outcomes (Table 3). The annual event rates were 0.97%
for posterior circulation ischemic stroke, 1.30% for an-
terior circulation ischemic stroke, 1.94% for hemorrhagic
stroke, 4.86% for all stroke, and 6.80% for composite car-
diovascular outcome (Table 3). The annual event rate of
ischemic stroke in the posterior circulation was signifi-
cantly higher in the symptomatic VAO stenosis group
than in the asymptomatic group (1.88% vs. 0%, p = 0.046).
Any other individual cardiovascular outcomes were not
different between the asymptomatic and symptomatic
VAO stenosis groups (Table 3). Using Kaplan-Meier
curves, the cumulative risks of posterior circulation12 months of follow-up
Baseline 3-month follow-up 12-month follow-up
151.0 ± 29.3 (n = 64) 124.5 ± 15.4 (n = 51)* 123.4 ± 13.8 (n = 42)*
84.6 ± 16.0 (n = 64) 71.0 ± 10.1 (n = 51)* 71.5 ± 8.8 (n = 42)*
171.8 ± 36.7 (n = 63) 141.0 ± 34.7 (n = 49)*
107.9 ± 29.7 (n = 59) 80.7 ± 31.3 (n = 27)*
43.3 ± 10.5 (n = 63) 44.8 ± 11.7 (n = 48)
8.0 ± 2.2 (n = 30) 7.0 ± 1.2 (n = 23)‡
55 45
42 (76.4) 37 (82.2)
53 (96.4) 41 (91.1)
36 (65.5) 33 (73.3)
152.6 ± 22.6 (n = 73) 123.3 ± 16.0 (n = 57)* 125.6 ± 14.8 (n = 49)*
82.4 ± 15.3 (n = 73) 69.9 ± 9.7 (n = 57)* 72.8 ± 10.6 (n = 49)*
185.8 ± 37.3 (n = 73) 148.0 ± 31.7 (n = 53)*
112.0 ± 31.2 (n = 70) 81.0 ± 27.5 (n = 30)*
44.9 ± 10.6 (n = 73) 47.1 ± 17.6 (n = 52)
8.3 ± 1.7 (n = 35) 7.3 ± 0.9 (n = 22)†
59 51
39 (66.1) 37 (72.5)
58 (98.3) 49 (96.1)
45 (76.3) 39 (76.5)
f evaluated patients.
< 0.05.
Table 3 Incidence and annual event rate of outcomes during follow-up















All stroke 15 (10.9) 9 (14.1) 6 (8.2) 4.86 (2.93–8.06) 6.02 (3.13–11.58) 3.77 (1.69–8.38) 0.367
Posterior circulation ischemic stroke 3 (2.2) 0 (0) 3 (4.1) 0.97 (0.31–3.01) 0.00 1.88 (0.61–5.84) 0.046
Anterior circulation ischemic stroke 4 (2.9) 3 (4.7) 1 (1.4) 1.30 (0.49–3.45) 2.01 (0.65–6.23) 0.63 (0.09–4.45) 0.277
Hemorrhagic stroke 6 (4.4) 4 (6.3) 2 (2.7) 1.94 (0.87–4.33) 2.68 (1.00–7.13) 1.26 (0.31–5.02) 0.367
Unknown stroke 2 (1.5) 2 (3.1) 0 (0) 0.65 (0.16–2.59) 1.34 (0.33–5.35) 0.00 0.088
Unstable angina/myocardial infarction 4 (2.9) 2 (3.1) 2 (2.7) 1.30 (0.49–3.45) 1.34 (0.33–5.35) 1.26 (0.31–5.02) 0.949
Vascular death 4 (2.9) 2 (3.1) 2 (2.7) 1.30 (0.49–3.45) 1.34 (0.33–5.35) 1.26 (0.31–5.02) 0.949
Composite cardiovascular outcome 21 (15.3) 11 (17.2) 10 (13.7) 6.80 (4.43–10.43) 7.36 (4.08–13.30) 6.28 (3.38–11.66) 0.714
Non–vascular death 14 (10.2) 8 (12.5) 6 (8.2) 4.53 (2.69–7.66) 5.36 (2.68–10.71) 3.77 (1.69–8.38) 0.512
*p-value was calculated from annual event rates of the asymptomatic and symptomatic groups.
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outcome according to the asymptomatic and symptomatic
VAO stenosis groups were plotted (Figure 2).
Cox proportional hazard analyses indicated that indi-
vidual vascular risk factors, ESRS, symptomatic stenosis
of VAO, and concurrent stenosis of other vertebrobasilar
or carotid circulation were not associated with any type
of stroke outcome, including posterior circulation ische-
mic stroke (data not shown). The presence of peripheral
arterial disease and ESRS were associated with the com-
posite cardiovascular outcome in the univariate Cox pro-
portional hazard analyses (Table 4). Multivariate Cox
proportional hazard analyses revealed that the significant
association with peripheral arterial disease disappeared
in model 1, and only ESRS was associated with compos-
































137 104 53 2 64 46
Figure 2 Long-term outcome of vertebral artery origin stenosis. The c
the composite cardiovascular outcome of all patients (A), the asymptomati
plotted using Kaplan-Meier curves.hazard ratio, per one point increase of the ESRS for the
composite cardiovascular outcome, was 1.46 (95% CI,
1.02-2.08, p = 0.036).
Discussion
CE-MRA for the evaluation of VAO
Among various noninvasive techniques, recent studies
have shown that CE-MRA may be the most accurate
technique for evaluating stenosis of the carotid artery
[21] or vertebral artery [22,23]. Compared to conven-
tional angiography, CE-MRA may have some limitations
in assessing the exact degree of stenosis at the VAO [24].
However, recent studies have shown reliable diagnostic ac-
curacy between conventional angiography and CE-MRA,
demonstrating a sensitivity of 88% and a specificity of 98%








28 2 73 58 25 1
umulative risk of posterior circulation ischemic stroke, all stroke, and
c stenosis group (B), and the symptomatic stenosis group (C) were
Table 4 Predictors of composite cardiovascular outcome in the univariate and multivariate Cox proportional hazard
analyses
Univariate analysis Multivariate analysis
Model 1 Model 2
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age (per 1 year) 1.01 (0.97–1.05) 0.720 1.00 (0.95–1.06) 0.893 -
Sex, male 0.95 (0.40–2.23) 0.901 0.77 (0.22–2.70) 0.678 0.83 (0.34–2.05) 0.685
Hypertension 2.27 (0.66–7.75) 0.181 2.10 (0.56–7.82) 0.271 -
Diabetes 2.21 (0.88–5.55) 0.082 1.89 (0.70–5.11) 0.208 -
Hyperlipidemia 1.32 (0.56–3.14) 0.522 1.31 (0.52–3.33) 0.570 1.54 (0.64–3.72) 0.340
Atrial fibrillation 1.39 (0.31–6.32) 0.669 1.56 (0.24–10.24) 0.642 1.19 (0.23–6.10) 0.837
Smoking 1.19 (0.49–2.90) 0.697 1.52 (0.40–5.77) 0.538 -
Previous stroke history 1.33 (0.51–3.44) 0.557 1.40 (0.51–3.82) 0.516 -
Coronary arterial disease 1.26 (0.45–3.59) 0.661 0.99 (0.31–3.17) 0.984 -
Peripheral arterial disease 4.99 (1.13–22.0) 0.034 8.29 (0.92–74.52) 0.059 -
ESRS (per 1) 1.38 (1.01–1.88) 0.045 - 1.46 (1.02–2.08) 0.036
Symptomatic stenosis of vertebral artery origin* 0.99 (0.41–2.39) 0.978 1.09 (0.40–2.95) 0.869 1.04 (0.40–2.74) 0.935
Concurrent vertebrobasilar stenosis‡ 1.61 (0.67–3.90) 0.287 1.12 (0.39–3.21) 0.837 1.35 (0.52–3.55) 0.540
Concurrent carotid stenosis‡ 0.90 (0.30–2.68) 0.848 0.41 (0.89–1.91) 0.256 0.65 (0.21–2.06) 0.467
*symptomatic stenosis compared to asymptomatic stenosis of vertebral artery origin.
†indicates the presence of concurrent severe stenosis or occlusion of the contralateral vertebral artery, or tandem stenosis of the intracranial vertebral artery or
basilar artery.
‡indicates the concurrent presence of more than 50% stenosis of at least one carotid artery.
ESRS Essen Stroke Risk Score.
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than 50% stenosis at the VAO [25,26]. In our study, the
concordance rate for selected patients who underwent
both CE-MRA and conventional angiography was accept-
able as high as 83.7%. Considering the relative invasiveness
of conventional angiography, CE-MRA may be a safe and
reliable alternative for the evaluation of VAO in patients
with acute ischemic stroke.
Prevalence of VAO stenosis
The prevalence of VAO stenosis is variable according to
different study populations and ranges from 7.6 to 44.4%
[3,5,24,27]. In a hospital-based cohort of patients with
atherosclerotic arterial disease who were enrolled in the
Second Manifestation of ARTerial disease (SMART)
study, 282 patients (7.6%) presented asymptomatic VAO
stenosis of more than 50% among a total of 3717 pa-
tients [5]. The presence of asymptomatic VAO stenosis
was more frequent in the subgroup that had previous is-
chemic stroke history compared to the subgroup that
did not (22/225, 9.8% vs. 260/3492, 7.4%) [5]. In a pro-
spective population-based study nested within the Ox-
ford Vascular Study, 16 patients (11.3%) had more than
50% stenosis at or near the VAO (9 at the vertebral ori-
gin and 7 near the origin) among a total of 141 patients
who had posterior circulation vascular events [24].Among 407 New England Medical Center Posterior Cir-
culation registry patients, 131 patients (32.1%) presented
more than 50% stenosis of the VAO [3]. In a non-
consecutive cohort consisted of various patients who
had TIA or stroke and some asymptomatic patients, the
prevalence of more than 50% stenosis of the proximal
vertebral artery was as high as 27.3% (33/121) in patients
who had anterior circulation infarcts and 44.4% (32/72)
in patients who had posterior circulation infarcts [27].
Taken together, VAO stenosis may be more prevalent in
patients who have had an ischemic stroke than in pa-
tients who have had other atherosclerotic arterial dis-
eases [5]. Among patients with ischemic stroke, VAO
stenosis may be more frequently observed in patients
who have had strokes in the posterior circulation com-
pared to patients who have had strokes in the anterior
circulation [27]. The prevalence of VAO stenosis (19.3%,
149/774) in our hospital-based cohort of patients with
acute ischemic stroke was comparable to those reported
in previous studies. In our study, the prevalence of VAO
stenosis was higher in patients with posterior circulation
ischemic stroke than that in patients with anterior circu-
lation ischemic stroke (31.7%, 85/268 posterior circula-
tion ischemic stroke vs.12.6%, 64/506 anterior or
simultaneous anterior and posterior circulation ischemic
stroke, p < 0.001). In particular, the prevalence of VAO
Table 5 Baseline characteristics of patients with vertebral








Age, years (mean ± SD) 70.4 ± 10.3 63.8 ± 11.5 < 0.001
Male (n,%) 73 (53.3) 97 (56.7) 0.566
Hypertension (n,%) 96 (70.1) 119 (69.6) 1.000
Diabetes (n,%) 66 (48.2) 75 (43.9) 0.491
Hyperlipidemia (n,%) 56 (40.9) 57 (33.3) 0.191
Atrial fibrillation (n,%) 6. (4.4) 5 (2.9) 0.547
Smoking (n,%) 61 (44.5) 90 (52.6) 0.170
Previous stroke history (n,%) 34 (24.8) 41 (24.0) 0.894
Coronary arterial disease 27 (19.7) 41 (24.4) 0.337
Peripheral arterial disease 5 (3.6) 6 (3.6) 1.000
ESRS (mean ± SD) 3.2 ± 1.5 2.9 ± 1.5 0.126
ESRS > 3 52 (38.0) 58 (33.9) 0.475
ESRS Essen Stroke Risk Score.
Published data of patients who had acute lacunar infarcts were used for the
comparison; data used with personal permission [14].
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lation ischemic stroke in our study cohort (31.7%) was
comparable to those from previous cohort studies con-
sisted of patients who had posterior circulation stroke s
(i.e., 11.3-44.4%) [3,24,27]. The higher incidence of VAO
stenosis in patients who had ischemic strokes in the pos-
terior circulation compared to the anterior circulation
may suggest VAO stenosis as a possible cause of ische-
mic stroke in the posterior circulation.
Low risk of posterior circulation ischemic stroke in
patients with VAO stenosis
With the development of medical treatments, thera-
peutic strategies for patients who have asymptomatic ca-
rotid stenosis have recently been reevaluated [28,29].
Owing to the low recurrence rate of stroke under
current optimal medical treatment, medical treatment
may be more cost-effective than carotid endarterectomy
or angioplasty and stenting for stroke prevention [28].
Given that VAO stenosis is a counterpart of proximal
carotid stenosis in the posterior circulation, it may be in-
teresting to compare our outcome data of the asymp-
tomatic VAO stenosis group to data from a recent study
of patients with asymptomatic carotid stenosis under the
best medical treatment [29]. In this population-based
study of patients who had TIA or stroke, the annual rate
of ipsilateral vascular events remained quite low in 101
patients with asymptomatic carotid stenosis of more
than 50% undergoing intensive medical treatment (i.e.,
ipsilateral TIA = 1.78% and ipsilateral stroke = 0.34%)
[29]. The pattern of stroke recurrence in this asymptom-
atic carotid stenosis study showed trends similar to the
asymptomatic VAO stenosis group of our study. The an-
nual rate of stroke recurrence in the vascular territory of
asymptomatic stenosis was very low in both studies (i.e.,
posterior circulation ischemic stroke in our asymptom-
atic VAO stenosis group = 0% vs. ipsilateral anterior cir-
culation stroke in the asymptomatic carotid study =
0.34%). Most recurrent strokes occurred in other vascu-
lar territories unrelated to asymptomatic stenosis (i.e., all
stroke in our asymptomatic VAO stenosis group = 6.02%
vs. other territory strokes in the asymptomatic carotid
stenosis study = 8.32%). In our study, recurrent ischemic
stroke in the posterior circulation occurred only in the
symptomatic VAO stenosis group, and the annual rate of
posterior circulation ischemic stroke was significantly
higher in the symptomatic VAO stenosis group (i.e., 0%
in the asymptomatic group vs. 1.88% in the symptomatic
group, p = 0.046). A higher prevalence of concurrent ver-
tebrobasilar stenosis in the symptomatic VAO stenosis
group could have contributed to the worse outcome of
the posterior circulation ischemic stroke.
We compared outcomes and variates of patients en-
rolled in our study to a previously published study thatused the same stroke registry in a similar period [14].
Patients enrolled in the previous study had acute lacunar
infarcts and were comparable to acute ischemic stroke
patients who did not have intra- or extra-cranial artery
stenosis. The baseline characteristics of patients with
acute lacunar infarcts were not different from those of
VAO stenosis except for age (Table 5). ESRS was slightly
higher in the VAO stenosis group, but this increase was
not statistically significant. The annual event rates of
outcomes were not different (Table 6). Considering the
most favorable outcomes were in patients with lacunar
infarcts among stroke subtypes [30], outcomes of the
VAO stenosis group comparable to those of lacunar in-
farcts may support a hypothesis that there will be a gen-
erally favorable outcome in patients with VAO stenosis.
Considering the potential risk of procedure-related
stroke or death in patients treated with angioplasty and
stenting, the low absolute risk of posterior circulation is-
chemic stroke in patients with asymptomatic VAO sten-
osis who are on the best medical treatment may not
warrant invasive treatment of asymptomatic VAO sten-
osis [5]. Because the majority of patients with asymp-
tomatic VAO stenosis die from vascular causes other
than posterior circulation ischemic stroke, therapeutic
strategies should be focused on reducing the total vascu-
lar risk [5]. In a long-term follow-up study of 96 patients
who had mainly VAO stenosis, recurrence of posterior
circulation ischemic stroke itself was low (i.e., 2% during
an average follow-up of 4.6 years) [10]. Instead, the risk
of cardiovascular complications was higher in these pa-
tients than in the matched normal population [10]. In
our study, individual vascular risk factors, symptomatic
Table 6 Annual event rate of outcomes during follow–up of patients with vertebral artery origin stenosis or acute lacunar
infarcts
Annual event rate, per 100 patient-years units (95% CI) P-value
Vertebral artery origin stenosis (n = 137) Acute lacunar infarcts (n = 169)
All stroke 4.86 (2.93–8.06) 3.38 (1.41–8.13) 0.486
Unstable angina/myocardial infarction 1.30 (0.49–3.45) 2.71 (1.02–7.21) 0.293
Vascular death 1.30 (0.49–3.45) 1.35 (0.34–5.41) 0.960
Composite cardiovascular outcome 6.80 (4.43–10.43) 6.77 (3.64–12.58) 0.990
Published data of patients who had acute lacunar infarcts were used for the comparison; data used with personal permission [14].
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robasilar or carotid circulation were not associated with
individual outcomes, including any type of stroke. In-
stead, ESRS, the sum of underlying multiple vascular risk
factors, was associated with composite cardiovascular
outcome.
Taken together, these results indicate that VAO sten-
osis itself may not be a specific risk factor for posterior
circulation ischemic stroke, especially when it is asymp-
tomatic. However, patients who have higher ESRS need
more clinical attention because of the potential of more
frequent future cardiovascular events.
Angioplasty and stenting for VAO stenosis
A recent systematic review reported favorable outcomes
of angioplasty and stenting in patients who had mostly
symptomatic extracranial vertebral artery stenosis: i.e.,
posterior circulation ischemic stroke (1.3%) and TIA
(6.5%) during the average follow-up period of 21 months
[18]. Despite the limitation of direct comparison to the
results of the systematic review, an annual event rate of
0.97% for posterior circulation ischemic stroke in our
patients who had optimal medical treatment (i.e., 0% in
the asymptomatic group and 1.88% in the symptomatic
group) does not seem to be inferior to the historical out-
come data of patients who underwent angioplasty and
stenting. Although angioplasty and stenting for VAO
stenosis are technically safe and feasible, data on the nat-
ural history of patients who have extracranial vertebral
artery stenosis are still limited. Moreover, little is known
about the most cost-effective treatment option. A ran-
domized trial that compares medical treatment to med-
ical treatment plus additional endovascular treatment is
necessary in the future. Because individual VAO stenosis
may have different clinical significance according to
whether the lesion is symptomatic or not, future study
subjects should be clearly defined regarding their symp-
tomatic status for VAO stenosis.
Despite the controversial results of previous studies
that focused on VAO stenosis as a possible embolic
source for ischemic stroke in the posterior circulation
[8,31], some patients with VAO stenosis may be at a
truly higher risk for posterior circulation stroke [9,12].Although there has been no clear consensus on the
management of VAO stenosis, the presence of concur-
rent severe cerebrovascular atherosclerosis has been
considered a reasonable indication for angioplasty and
stenting under the potential high risk of recurrent ische-
mic stroke in the posterior circulation [8,18,32]. In our
study cohort, the 12 patients who underwent angioplasty
and stenting within 1 month after stroke-onset were ex-
cluded from our study. A decision for the angioplasty
and stenting was based on the individual case-by-case
situations: as procedures for acute intra-arterial thromb-
olysis in 3 patients and concurrent vertebrobasilar and/
or carotid atherosclerosis in 9 patients. All of those pa-
tients had acute ischemic stroke in the posterior circula-
tion, and they were potentially at high risk for recurrent
stroke. Exclusion of those patients from the symptomatic
VAO stenosis group might have biased our results.
Therefore, type II error may have occurred in our study
because of the small number of subjects, very low recur-
rence rate of posterior circulation ischemic stroke, and
the exclusion of some high risk patients. However, the
presence of concurrent vertebrobasilar or carotid athero-
sclerosis was not associated with the recurrence of pos-
terior circulation ischemic stroke. One-sided preferences
for angioplasty and stenting in patients who have VAO
stenosis, simply because they have concurrent vertebro-
basilar or carotid arterial stenosis, may need more care-
ful consideration.
Limitations of our study
The number of enrolled patients was relatively small in
our study. Although the enrolled patients were prospect-
ively collected from the stroke registry with predefined
outcome follow-ups, the data were analyzed retrospect-
ively. Therefore, some degree of bias is inevitable.
Recently, clinical concepts of optimal medical treat-
ment have been introduced: so-called best medical treat-
ment [29], intensive contemporary medical therapy [33],
medical intervention [28], aggressive medical manage-
ment [34], and others. However, specifically detailed
guidelines for optimal medical treatment in a real clin-
ical practice have not yet been established. Although we
tried to provide optimal medical treatment for all
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prevention, our medical treatment may have not been
optimal enough in some cases.
Conclusions
Long-term outcome of more than 50% stenosis of VAO
in patients who had acute ischemic stroke was generally
favorable with optimal medical treatment. Additionally,
ESRS was a predictor for the composite cardiovascular
outcome. The clinical significance of VAO stenosis may
be different according to the symptomatic status of VAO
stenosis. Asymptomatic VAO stenosis may not be a spe-
cific risk factor for recurrent ischemic stroke in the pos-
terior circulation. However, when VAO stenosis is
observed in patients who had concurrent ischemic
strokes in the posterior circulation (i.e., symptomatic
VAO stenosis), more clinical attention on VAO stenosis
may be needed because this condition could be a poten-
tial source of recurrent stroke.
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